AstralBio

AstralBio is a privately-held biotechnology company founded by Patrick Crutcher and several former team members of ValenzaBio and AlmataBio. AstralBio's mission is to develop first-in-class or best-in-class drugs for the treatment of cardiometabolic and immune-mediated diseases. The company plans to leverage iBio's established machine learning platform to accelerate the advancement of new therapeutic targets, thereby transforming patient care.